Mondher Toumi

Aix-Marseille Université — France

Economics, Econometrics and Finance · Social Sciences

47h-index8.5kcitations831works1.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(401), Pharmaceutical Economics and Policy(299), Schizophrenia research and treatment(82), Pharmaceutical studies and practices(72), Biomedical Ethics and Regulation(63)

Publications830 total

Cost-effectiveness of the ABCStroke pathway in ischaemic stroke care: a UK pilot analysis

European Heart Journal - Quality of Care and Clinical Outcomes·2026Open Access

Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UK

Advances in Therapy·2025

PT27 Synthetic Data Generation vs. Simulated Treatment Comparison: Assessment of the Performance of a Novel Approach for Unanchored Indirect Treatment Comparisons

Value in Health·2025

HTA107 Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics

Value in Health·2025

HTA245 Navigating Joint Clinical Assessment in Europe: Strategic Roadmap and Recommendations for Health Technology Developers

Value in Health·2025

HTA272 Predicting SMC Appraisal Outcomes Using Machine Learning: A Model to Support Early Market Access Strategy

Value in Health·2025

HTA198 Importance of Decisional Context in the Health Technology Assessment (HTA) of Ultra-Orphan Drugs

Value in Health·2025

EPH265 Tropical Virus in France: Dengue Cases on the Rise

Value in Health·2025

P16 Beyond PFS and OS: Recovering Pre- and Post-Progression Survival From Survival Curves

Value in Health·2025

EE315 Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK

Value in Health·2025

The RELIANT checklist: a novel approach to revealing implicit factors in HTA deliberations

Health Policy OPEN·2025Open Access

Energy Efficiency Management and Greenhouse Gas Emissions in Industrialized Countries: A panel CS - ARDL Approach

Journal of Ecohumanism·2025Open Access

Epistemological Tensions in the EU HTA Joint Clinical Assessment: The Illusion of Judgment-Free Evaluation

Preprints.org·2025Open Access

Managed Entry Agreements for Pharmaceutical Products in Three Maghreb Countries: Payer and Supplier Perspectives

Journal of Market Access & Health Policy·2025Open Access

The European Union’s Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks

Preprints.org·2025Open Access

The Acceptance of Overall Survival Extrapolation Methods in Solid Tumor Treatments by Health Technology Assessment Agencies in England, France, and Australia between 2017 and 2022

Medical Decision Making·2025

EE358 Validation of a Flexible Partitioned Survival and 3-State Markov Model for Cost-Effectiveness Analyses in Oncology

Value in Health·2025

HTA20 Drivers of High ICERs in SMC Appraisals

Value in Health·2025

MSR57 Extended MAIC to Validate Results in Cases of Poor Population Overlap: An Application to Compare Prophylactic Treatments in Pediatric Patients With Hemophilia A

Value in Health·2025Open Access

RWD20 Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in Poland in Comparison With Efficacy Reported in Clinical Trials

Value in Health·2025

page 1 of 42Next →

Frequent Co-authors

Matthias C. Angermeyer(12), Paul Bebbington(8), Traolach Brugha(8), A. Millier(8), Jean‐Michel Azorin(7), Sonia Johnson(6), Reinhold Kilian(6), C. Rémuzat(6), Samuel Aballéa(6), Pascal Auquier(5), Dirk Heider(5), Steven Marwaha(3), C. François(3), Christiane Roick(3), A. Kornfeld(3), Steven Simoens(3), Monique Dabbous(3), D. Charpin(2), A. Lanteaume(2), D. Vervloët(2)